<DOC>
	<DOCNO>NCT02508935</DOCNO>
	<brief_summary>Phase 4 , multicenter , open-label , multiple-dose study pharmacokinetics ( PK ) safety XARTEMIS XR postsurgical adolescent subject age 12 17 year moderate severe acute pain . The study assess safety administer multiple dos XARTEMIS XR population .</brief_summary>
	<brief_title>PK Safety Study XARTEMISÂ® XR ( 7.5 mg Oxycodone HCl/325 mg APAP ) Postsurgical Adolescent Subjects With Moderate Severe Acute Pain</brief_title>
	<detailed_description />
	<mesh_term>Acute Pain</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Acetaminophen , hydrocodone drug combination</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Inclusion criterion : 1 . Male nonpregnant , nonlactating female 12 17 year age . 2 . Minimum weight 100 pound ( 45 kg ) ; body mass index ( BMI ) &gt; 5 % &lt; 95 % age . 3 . Moderate severe acute pain ( determined Numerical Pain Rating scale [ NPRS ] ; must level 4 ) surgical procedure require hospitalization . 4 . If , childbearing/reproductive potential , must abstain unprotected sexual activity study 2 week study exit . 5 . Females childbearing potential must negative pregnancy test . 6 . Subject 's legally authorize representative ( eg , parent , legal guardian ) must sign parental permission/informed consent subject must sign assent . 7 . Subject subject 's parent/legal guardian must able read , understand , follow study procedure requirement communicate meaningfully English . Exclusion criterion : 1 . Subject vulnerable population ( include mentally disabled child ) , pediatric population . 2 . Subject require surgery could influence study outcome . 3 . Abnormal electrocardiogram ( ECG ) . 4 . Screening pulse oximetry read &lt; 95 % awake . 5 . Has presence human immunodeficiency virus ( HIV ) indication hepatitis A , B C. 6 . Lab value great 2 time upper limit normal . 7 . History renal disease bleed clot disorder condition . 8 . Known suspected alcoholism , marijuana illicit drug abuse misuse within 2 year screen . 9 . Smoked used nicotinecontaining product within 6 month prior screen . 10 . Psychiatric disorder , major depression disorder , anxiety disorder , psychotic disorder within 6 month prior screen . A history attention deficit hyperactivity disorder require medication acceptable . 11 . Diagnosis epilepsy seizure disorder . 12 . Previous cardiothoracic surgery . 13 . Conditions might specifically contraindicate require caution use OC , APAP , and/or ibuprofen . 14 . Drug allergy , hypersensitivity , intolerance include OC , APAP , ibuprofen excipients , opioid drug product . 15 . Donated significant loss whole blood ( 480 mL ) within 30 day plan donate blood plasma course study . 16 . Pathologic , iatrogenic surgical condition would compromise subject 's ability swallow , absorb , metabolize , excrete XARTEMIS XR . 17 . History GI event within 6 month prior screen . 18 . Subject use product contain OC APAP within 48 hour prior first dose XARTEMIS XR . 19 . Any medical condition , abnormal vital sign ( blood pressure , pulse rate , respiratory rate ) , body temperature , pulse oximetry ; physical examination ECG finding screen would preclude safe participation clinical study . 20 . Received investigational product device within 30 day screen , schedule receive investigational device another investigational drug course study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>